Key result
Doxorubicin caused a 30% decrease in ejection fraction and a nearly 40% reduction in fractional shortening in rats with fructose overload, but not in control rats.
Why the study?
To examine whether metabolic syndrome-like conditions in fructose-overloaded rats modify doxorubicin-induced cardiotoxic effects and cardiac transporter expression.
Does doxorubicin cause greater cardiotoxicity in a rat model of metabolic syndrome compared to controls?
Does doxorubicin cause greater cardiotoxicity in a rat model of metabolic syndrome compared to controls?
Metabolic syndrome-like conditions induced by fructose overload exacerbate doxorubicin-induced cardiotoxicity in rats, potentially due to enhanced lipid peroxidation and reduced P-gp expression.
Supports metabolic syndrome as doxorubicin cardiotoxicity modifier in rats; leaves open translation to patients.
The aim of the present work was to examine whether metabolic syndrome-like conditions in rats with fructose (F) overload modify the cardiotoxic effects induced by doxorubicin (DOX) and whether the treatment altered the expression of P-gp, breast cancer resistance protein, and organic cation/carnitine transporters in the heart. Male Sprague-Dawley rats received either tap water (control group [C]; n = 16) or water with F 10% wt/vol (n = 16) during 8 weeks. Three days before being killed, the animals received a single dose of DOX (6 mg/kg, ip, md) (C-DOX and F-DOX groups) or vehicle (VEH; ISS 1 mL/kg BW; ip) (C-VEH and F-VEH groups) (n = 8 per group). F overload enhanced thiobarbituric acid-reactive substance levels in the left ventricle, and DOX injection further increased those values. DOX did not alter thiobarbituric acid-reactive substance production in C animals. DOX caused a decrease of 30% in the ejection fraction and a nearly 40% reduction in the fractional shortening in F animals, but not in C rats. Cardiac tissue levels of P-gp decreased by about 30% in F rats compared with the C groups. DOX did not modify cardiac P-gp expression. Breast cancer resistance protein and organic cation/carnitine transporter (OCTN 1/2/3) protein levels did not change with either F or DOX. It is suggested that DOX could cause greater cardiotoxicity in rats receiving F, probably due to enhanced cardiac lipid peroxidation and lower expression of cardiac P-gp. These results support the hypothesis that the cardiotoxicity of DOX could be increased under metabolic syndrome-like conditions or in other health disorders that involve cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Ogonowski et al. (2021) studied Metabolic syndrome and doxorubicin cardiotoxicity (n=32). Doxorubicin vs. Vehicle was evaluated on Ejection fraction and fractional shortening. Doxorubicin caused a 30% decrease in ejection fraction and a nearly 40% reduction in fractional shortening in rats with fructose overload, but not in control rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: